Ovid Therapeutics (NASDAQ: OVID) revenue
Ovid Therapeutics reported revenue of $7.3m for fiscal 2025, 1,181.3% more than in fiscal 2024 ($0.6m). Since fiscal 2020 its revenue has fallen by 42.5%, an average decline of 10.5% a year.
Ovid Therapeutics has grown its revenue for 2 years in a row, and its best year of the last 6 was fiscal 2021. The biggest drop was in fiscal 2022, −99.3%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $7.3m | +1,181.3% | −$42.4m | −585.2% |
| 2024 | $0.6m | +44.4% | −$61.9m | −10,933.7% |
| 2023 | $0.4m | −73.9% | −$59.3m | −15,122.7% |
| 2022 | $1.5m | −99.3% | −$55.5m | −3,696.4% |
| 2021 | $208.4m | +1,551.6% | $124.2m | 59.6% |
| 2020 | $12.6m | — | −$81.4m | −645.4% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Ovid Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, Ovid Therapeutics ranks 376th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Ovid Therapeutics, 1,181.3%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 374th | Aclaris Therapeutics | $7.8m | −58.2% |
| 375th | Xenon Pharmaceuticals | $7.5m | — |
| 376th | Ovid Therapeutics | $7.3m | 1,181.3% |
| 377th | Whitehawk Therapeutics | $7.1m | −72.5% |
| 378th | Immunome | $6.9m | −23.2% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Ovid Therapeutics
- How much revenue did Ovid Therapeutics make in fiscal 2025?
- Ovid Therapeutics reported revenue of $7.3m for fiscal 2025, compared with $0.6m in fiscal 2024.
- How much has the revenue of Ovid Therapeutics fallen?
- Between fiscal 2020 and fiscal 2025 it went from $12.6m to $7.3m: 42.5% less, an average decline of 10.5% a year.
- What was the best year for revenue at Ovid Therapeutics?
- Of its last 6 fiscal years, fiscal 2021, with $208.4m.
- Where does Ovid Therapeutics rank in its sector by revenue?
- It ranks 376th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Ovid Therapeutics come from?
- From the annual report (Form 10-K) that Ovid Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Ovid Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Ovid Therapeutics: the Ovid Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.